[Form 4] Protagonist Therapeutics, Inc Insider Trading Activity

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Protagonist Therapeutics Chief Financial Officer Asif Ali exercised employee stock options and sold shares on the same day. He exercised options to acquire 19,500 shares of common stock at $19.19 per share and 5,265 shares at $12.17 per share. He then sold 24,765 shares of common stock in open-market transactions at a weighted average price of $104.24 per share, with individual trades ranging from $104.00 to $104.465. After these transactions, he directly owned 60,753 common shares, which include 433 shares acquired under the company’s 2016 Employee Stock Purchase Plan on March 9, 2026.

Insider Trade Summary

Net Seller: 24,765 shares ($2,581,504)

Net Sell 5 txns

Insider Ali Asif

Role Chief Financial Officer

Sold 24,765 shs ($2.58M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	19,500	$0.00	--
Exercise	Stock Option (right to buy)	5,265	$0.00	--
Exercise	Common Stock	19,500	$19.19	$374K
Exercise	Common Stock	5,265	$12.17	$64K
Sale	Common Stock	24,765	$104.24	$2.58M

Holdings After Transaction: Stock Option (right to buy) — 31,300 shares (Direct); Common Stock — 80,253 shares (Direct)

Footnotes (1)

Includes an aggregate of 433 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2026. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $104.00 to $104.465. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The stock option was granted to the Reporting Person on April 18, 2022, one quarter vested on April 18, 2023 and the remaining three quarters vest in equal monthly installments through April 18, 2026, subject to the Reporting Person's continued service to the Issuer. The stock option was granted to the Reporting Person on January 16, 2023 and vests in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service to the Issuer.

Form 4 Insider Transactions: What Each Field Means →

03/27/2026 - 07:33 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ali Asif

(Last)

(First)

(Middle)

C/O PROTAGONIST THERAPEUTICS, INC.

7707 GATEWAY BLVD., SUITE 140

(Street)

NEWARK

CALIFORNIA

94560-1160

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protagonist Therapeutics, Inc [ PTGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/26/2026		M		19,500	A	$19.19	80,253⁽¹⁾	D
Common Stock	03/26/2026		M		5,265	A	$12.17	85,518	D
Common Stock	03/26/2026		S		24,765	D	$104.24⁽²⁾	60,753	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$19.19	03/26/2026		M			19,500	⁽³⁾	04/18/2032	Common Stock	19,500	$0	31,300	D
Stock Option (right to buy)	$12.17	03/26/2026		M			5,265	⁽⁴⁾	01/15/2033	Common Stock	5,265	$0	13,282	D

Explanation of Responses:

1. Includes an aggregate of 433 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2026.

2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $104.00 to $104.465. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

3. The stock option was granted to the Reporting Person on April 18, 2022, one quarter vested on April 18, 2023 and the remaining three quarters vest in equal monthly installments through April 18, 2026, subject to the Reporting Person's continued service to the Issuer.

4. The stock option was granted to the Reporting Person on January 16, 2023 and vests in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service to the Issuer.

	/s/ Matthew Gosling, Attorney-in-Fact for Asif Ali	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did PTGX CFO Asif Ali report?

Asif Ali reported exercising stock options and selling shares. He exercised options for 24,765 Protagonist Therapeutics common shares and sold 24,765 shares in open-market trades, while remaining a direct shareholder after the transactions.

How many Protagonist Therapeutics (PTGX) shares did the CFO sell?

He sold 24,765 shares of Protagonist Therapeutics common stock. These were open-market or private transactions reported with a weighted average sale price, and he continued to hold a significant direct position afterward.

At what prices did the PTGX CFO sell his shares?

The weighted average sale price was $104.24 per share. Footnotes state the individual trades occurred at prices ranging from $104.00 to $104.465 per share across multiple transactions on the same date.

What stock options did the Protagonist Therapeutics CFO exercise?

He exercised options to acquire 19,500 shares at an exercise price of $19.19 and 5,265 shares at $12.17. These options were granted in 2022 and 2023 and vest over time, subject to continued service.

How many PTGX shares does the CFO hold after these transactions?

Following the reported exercises and sales, Asif Ali directly owned 60,753 shares of Protagonist Therapeutics common stock. This total includes 433 shares acquired through the company’s 2016 Employee Stock Purchase Plan on March 9, 2026.

Were the PTGX CFO’s option grants time-vested?

Yes. One option grant from April 18, 2022 vested one quarter on April 18, 2023, with the rest vesting monthly through April 18, 2026. A second grant from January 16, 2023 vests in 48 equal monthly installments.